The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience

BackgroundFurmonertinib is the standard treatment option in the first-line setting for advanced non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations in China. However, there are limited real-world data available.MethodsWe conducted a retrospective study...

Full description

Bibliographic Details
Main Authors: Ningning Yan, Sanxing Guo, Siyuan Huang, Huixian Zhang, Xingya Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Oncology
Subjects:
furmonertinib
non-small cell lung cancer
EGFR-mutated
epidermal growth factor receptor
real-world setting
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1331128/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1331128/full

Similar Items